Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease

S. Javad Sayedi (Mashhad, Islamic Republic of Iran), M. Reisi (Mashhad, Islamic Republic of Iran), M. Modaresi (Mashhad, Islamic Republic of Iran), Z. Aghaii (Mashhad, Islamic Republic of Iran), S. Mirlohi (Mashhad, Islamic Republic of Iran), H. Rafiemanesh (Mashhad, Islamic Republic of Iran), G. Azizi (Mashhad, Islamic Republic of Iran)

Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Session: Clinical monitoring and new therapies for cystic fibrosis
Session type: E-poster session
Number: 369
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Javad Sayedi (Mashhad, Islamic Republic of Iran), M. Reisi (Mashhad, Islamic Republic of Iran), M. Modaresi (Mashhad, Islamic Republic of Iran), Z. Aghaii (Mashhad, Islamic Republic of Iran), S. Mirlohi (Mashhad, Islamic Republic of Iran), H. Rafiemanesh (Mashhad, Islamic Republic of Iran), G. Azizi (Mashhad, Islamic Republic of Iran). Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease. 369

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020
Year: 2021



Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009


Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016


Doxycycline improves clinical outcomes during cystic fibrosis exacerbations
Source: Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016
Year: 2017



Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016



Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012


Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016
Year: 2017



Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016

Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006

Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007


Efficacy of long-acting bronchodilator inhalation on postoperative pulmonary function and quality of life in lung cancer patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Actual challenges in thoracic surgery
Year: 2008


A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP
Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Year: 2012

Inhaled glutathione tolerability and efficacy in patients with cystic fibrosis
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease
Year: 2012

Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 767s
Year: 2006

The efficacy and side-effects of varenicline in patients with mild to moderate chronic obstructive pulmonary diseases
Source: Annual Congress 2010 - Passive smoking
Year: 2010


The efficacy and tolerability of inhaled hypertonic saline in children with cystic fibrosis
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020

Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012

Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016